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Background. Nonmotor symptoms (NMS) of Parkinson’s disease (PD) may be more debilitating than motor symptoms. The
purpose of this study was to determine the frequency and corecognition of NMS among our advanced PD cohort (patients
considered for deep brain stimulation (DBS)) and caregivers. Methods. NMS-Questionnaire (NMS-Q), a self-administered
screening questionnaire, and NMS Assessment-Scale (NMS-S), a clinician-administered scale, were administered to PD patients
and caregivers. Results. We enrolled 33 PD patients (23 males, 10 females) and caregivers. The most frequent NMS among patients
usingNMS-Qweregastrointestinal(87.9%),sleep(84.9%),andurinary(72.7%),whilethemostfrequentsymptomsusingNMS-S
were sleep (90.9%), gastrointestinal (75.8%), and mood (75.8%). Patient/caregiver scoring correlations for NMS-Q and NMS-S
were 0.670 (P<0.0001) and 0.527 (P = 0.0016), respectively. Conclusion The frequency of NMS among advanced PD patients and
correlation between patients and caregivers varied with the instrument used. The overall correlation between patient and caregiver
was greater with NMS-Q than NMS-S.
1.Introduction
It is becoming increasingly recognized that PD is a multidi-
mensional disease and that nonmotor symptoms (NMS) can
potentially aﬀect quality of life as much or more than motor
dysfunction[1].NMSmaybeunderrecognizedbyphysicians
and include such important features as cognitive impair-
ment, depression, and apathy. A recent paper by Carter and
colleaguesfoundthatNMSmaycontributemoretocaregiver
strain and depression than motor symptoms [2]. The NMS
Questionnaire (NMS-Q) was devised to screen patients and
wasrecentlyvalidated[3].Subsequently,anNMSAssessment
Scale for Parkinson’s disease (NMS-S) has been created to
assess the frequency and severity of NMS in PD [4].
In a large, recent multicenter study by Barone and
colleagues, 98.6% of PD patients had at least one NMS [5].
However, studies surveying NMS speciﬁcally in advanced
PD patients have been limited. We suspected that, in this
subset of PD patients, NMS may play even greater role and
m a yb em o r ep r e v a l e n t .
We chose a population with relatively advanced PD, and
we aimed in this study to determine the frequency of NMS
in PD patients and to evaluate the correlation between PD
patient and caregiver perceptions of NMS.
2. Methods
Consecutive advanced PD patients with severe motor
ﬂuctuations who were candidates undergoing evaluation
for either unilateral STN or GPI stimulation were included.
All patients signed informed consents to have their data
stored in a database in accordance with the Declaration of2 Parkinson’s Disease
Helsinki. All subjects were between the ages of 18 to 85,
had diagnosis of idiopathic PD conﬁrmed by a movement
disorders specialist (UK Brain Bank criteria), and also
had a documented greater than 30% improvement in
motor performance following levodopa administration (as
measured by the Uniﬁed Parkinson’s Disease Rating Scale
Part III). Subjects were excluded from DBS implantation
and consequently from this study if they had signiﬁcant and
active psychiatric disease after a structured clinical interview
(SCID) or if demented (DRS score of <130 or demented
based on neuropsychological proﬁle).
The NMS-S and NMS-Q were separately administered
to each subject and caregiver. The NMS-S (clinically driven
questionnaire) was administered by a trained member of
the movement disorders team just prior to DBS surgery.
Patients were separated from their caregivers during scale
and questionnaire administration.
The NMS-Q form lists NMS symptoms with a “yes” or
“no” format. “Yes” answers are assigned one point; “no”
answers are assigned 0 points. The subsets were divided
in an attempt to better match comparison to the NMS-
S as follows: questions 1, 3, and 4–7 were grouped under
the gastrointestinal symptoms subset; questions 8-9 were
grouped under the urinary symptoms subset; questions 2,
10-11, and 27-28 were grouped under the miscellaneous
symptoms subset; questions 12-13 and 15 were grouped
under the cognition symptoms subset; questions 16-17 were
grouped under the mood symptoms subset; questions 18-19
were grouped under the sexual dysfunction symptoms subset;
questions 20-21 were grouped under the cardiovascular/falls
symptoms subset; questions 22–26 were grouped under the
sleep symptoms subset; questions 14, 29-30 were grouped
under perceptual symptoms subset.
The NMS-S not only assesses if NMS are present, but
the frequency (range of 0–4) and severity (range of 0–3)
are also rated. If the product of frequency x severity is 1 or
greater, then 1 point is assigned. The NMS-S was designed
for patients to assess their symptoms and not speciﬁcally
for caregiver assessment. Using the NMS-S form, the subsets
were divided as follows: questions 1-2 were grouped under
the cardiovascular/falls symptom subset; questions 3–7
were grouped under the sleep/fatigue symptoms subset;
questions 8–14 were grouped under the mood symptoms
subset; questions 15–17 were grouped under the perceptual
symptoms subset; questions 18–20 were grouped under the
cognition symptoms subset; questions 21–23 were grouped
under the gastrointestinal symptoms subset; questions
24–26 were grouped under the urinary symptoms subset;
questions 27-28 were grouped under the sexual dysfunction
symptoms subset; questions 29–32 were grouped under the
miscellaneous symptoms subset.
Percent prevalence was calculated by form (NMS-Q
or NMS-S) and by scorer (patient or caregiver). For
each domain and the total score of NMS-Q and NMS-
S, Spearman’s rank correlation coeﬃcient was evaluated
between patient and caregiver scoring and tested whether the
correlation was signiﬁcantly diﬀerent from zero.
3. Results
Thirty-three PD patients and their caregivers were included
in the study. Twenty-six patients eventually underwent
STN implantation at our institution. The remaining seven
patients subsequently underwent GPi implantation. The
average age of PD patients who participated was 61.3 years
± 8.1. Twenty three patients were men, and 10 patients were
women. The average oﬀ-medication UPDRS motor score at
baseline was 40.3 points ± 11.9.
3.1. NMS-Q. Table 1 summarizes the prevalence and cor-
relation of NMS by patients and caregivers. According to
patients, the most common NMS-Q items were GI (87.9%),
sleep (84.9%), and urinary (72.7%) symptoms. The least
prevalent NMS identiﬁed by PD patients were perceptual
(which included diplopia and delusional thoughts) (18.2%),
mood (48.5%), cardiovascular/falls (54.6%) and sexual
(54.6%) symptoms.
According to caregivers using the NMS-Q, the most
prevalent NMS symptoms were sleep (90.9%), GI (81.8%),
and miscellaneous (which included unexplained pain, anos-
mia, weight loss, and excessive sweating) (69.7%) items. The
least prevalent NMS caregivers identiﬁed were perceptual
(15.2%), cardiovascular (42.4%), and mood (54.6%) symp-
toms.
3.2. NMS-S. Table 1 summarizes the prevalence and cor-
relation of NMS by patients and caregivers. According to
patients, the most common NMS using the NMS-S were
sleep (90.9%), GI (75.8%), and mood (75.8%) symptoms.
The least prevalent NMS in PD patients were perceptual
(18.2%), cardiovascular (45.5%), and sexual (45.5%) symp-
toms.
Using the NMS-S, caregivers identiﬁed sleep (93.9%), GI
(72.7%), and mood (72.7%) and cognition (69.7%) symp-
toms most commonly. The least prevalent NMS that their
caregivers identiﬁed was perceptual (15.2%), cardiovascular
(33.3%), and urinary (48.5%) symptoms.
3.3. Patient and Caregiver Correlations. The highest corre-
lation of identiﬁed NMS symptoms using NMS-Q between
patients and their caregivers was with mood (0.65), sleep
(0.62), urinary (0.62), and miscellaneous (0.54) symptoms.
The lowest correlation of identiﬁed NMS symptoms using
NMS-Q between patients and their caregivers was with
cardiovascular (0.36), sexual (0.42), perceptual (0.46), and
gastrointestinal (0.53) symptoms (Table 1).
The highest correlation of identiﬁed NMS symptoms
using NMS-S between patients and their caregivers was
with cognition (0.62), mood (0.55), and sexual symptoms
(0.50). The lowest correlation of identiﬁed NMS symptoms
using NMS-S between patients and their caregivers was with
miscellaneous (0.38), cardiovascular (0.39), and perceptual
subsets (0.40) (Table 1).
Spearman’s correlation coeﬃcient of NMS-Q scores
between patient and caregiver was 0.670 (P value < 0.0001).
Spearman’s correlation coeﬃcient of NMS-S was 0.527
(P value = 0.0016).Parkinson’s Disease 3
Table 1: Frequency of nonmotor symptoms. In the NMS-Q, at least 1 question in the category is “yes.” In the NMS-S, Severity “Frequency”
is greater than 0 in at least 1 item in the subgroups.
NMS-Q Patient evaluation Caregiver evaluation Correlation Pv a l u e
Percent prevalence Percent prevalence
Gastrointestinal 87.9% 81.8% 0.53 0.002
Sleep 84.9% 90.9% 0.62 0.0001
Urinary 72.7% 63.6% 0.62 0.0001
Miscellaneous∗ 69.7% 69.7% 0.54 0.001
Cognition 63.6% 66.7% 0.46 0.007
Sexual 54.6% 57.1% 0.42 0.03
Cardiovascular/falls 54.6% 42.4% 0.36 0.04
Mood 48.5% 54.6% 0.65 0<.0001
Perceptual∗∗ 18.2% 15.2% 0.46 0.007
NMS-S Patient evaluation Caregiver evaluation Correlation Pv a l u e
Percent prevalence Percent prevalence
Sleep/Fatigue 90.9% 93.9% 0.46 0.01
Gastrointestinal 75.8% 72.7% 0.48 0.005
Mood 75.8% 72.7% 0.55 0.0009
Miscellaneous∗∗∗ 72.7% 66.7% 0.38 0.03
Cognition 60.6% 69.7% 0.62 0.0001
Urinary 57.6% 48.5% 0.47 0.01
Sexual 45.5% 53.6% 0.50 0.01
Cardiovascular/falls 45.5% 33.3% 0.39 0.02
Perceptual∗∗∗∗ 18.2% 15.2% 0.40 0.02
∗Refers to miscellaneous subset in NMS-Q that includes questions about change in smell, unexplained pain, unexplained weight change, swelling of legs, and
excessive sweating.
∗∗Refers to perceptual subset in NMS-Q that includes questions about diplopia and delusional thoughts.
∗∗∗Refers to miscellaneous subset in NMS-S that includes questions about unexplained pain, change in smell, unexplained weight change, and excessive
sweating.
∗∗∗∗Refers to perceptual subset in NMS-S that includes questions about hallucinations, delusional beliefs, and diplopia.
4. Discussion
The most frequent NMS in Chaudhuri’s tested cohort of
PD patients using the NMS-Q included nocturia (66.7%),
urinary urgency (61%), constipation (46.7%), memory
(43.9%), and sadness (44.7%) [3]. Further, in the Chaudhuri
and Martinez-Martin cohort, the most prevalent symp-
toms using the NMS-S included nocturia (59.5%), urinary
urgency (53.6%), constipation (50.2%), depression (48.2%),
insomnia (44.3%), and concentration (44%) [4]. A compar-
ison to our cohort of advanced (presurgical) PD patients
reveals similar ﬁndings but diﬀerent rank order. When using
the NMS-Q, patients in our study reported gastrointestinal,
sleep, and urinary symptoms, and when using the NMS-
S, PD patients reported sleep, gastrointestinal, and mood
symptoms most frequently. The reasons for the diﬀerences
include diﬀerent cohorts, diﬀerent disease severities, and a
diﬀerent demographic population. Also this advanced PD
patient population was screened for cognitive ﬁndings and
excludedforseveremooddisorderspriortoDBSsurgery,and
this may have also accounted for some of the diﬀerences.
The frequency of NMS among advanced PD patients
varied in our study depending on the type of instrument
utilized. For example, the frequency of mood symptoms
was among the top 3 in the NMS-S, but in the bottom 3
in the NMS-Q. This could be a reﬂection of the diﬀerence
of emphasis between the scales. In the NMS-Q, there were
2 questions that made up the mood subset, while, in the
NMS-Stherewere7.Devotingmorequestionstoaparticular
symptom may increase sensitivity of the instrument for
identifying milder manifestations of diﬃculty. In another
example, in the NMS-Q scale, the gastrointestinal subset was
composed of 9 questions, while in the NMS-S scale, the
gastrointestinal subset was composed of only 3 questions.
Finally, another important diﬀerence is that NMS-Q is
patient driven while the NMS-S is clinician driven. In
the mood example, clinician interpretation of a patient’s
answer may impact reporting diﬀerently than self-reported
information. Self-report for items such as sexual diﬃculties
may be more likely to capture full disclosure than face-
to-face reporting, within a clinician-administered scale. For
thesereasons,theNMSfrequenciesdiﬀerandareinstrument
driven if they are compared head to head as a screening tool.
This methodology of this study simpliﬁes the results of the
NMS-S,whichisdesignedtoassessimpactoftheNMSrather
than simply screening for its presence as in the NMS-Q.
The correlation of NMS between patients and care-
givers was also variable depending on the instrument and
the symptom subset. In general, there was higher overall
correlation in identifying NMS between PD patients and4 Parkinson’s Disease
caregivers using the NMS-Q than with NMS-S. The NMS-
Q had 5 subsets where the correlation between patient and
caregiver responses was greater than 0.50, while the NMS-S
had only 3 reaching this level. The 3 subsets with the highest
patient/caregiver correlation using NMS-Q were mood,
sleep, and urinary symptoms, and this diﬀered from the 3
subsets with the highest patient/caregiver correlation using
NMS-S where cognition, mood, and sexual items emerged.
Of these most correlated NMS, only mood was within the
highest correlated symptoms when using both instruments.
The lack of correlation using the other symptom subsets
between the patients and their caregivers may have been due
to the caregiver’s ability to recognize but not accurately rank
the severity of symptoms close to how patients would report
them. The NMS-Q is useful to screen for the presence of
nonmotor symptoms in Parkinson’s patients but does not
reveal the extent that these symptoms aﬀect quality of life.
The NMS-S on the other hand takes into consideration the
factors of duration and severity of symptoms that are present
andextentthatitaﬀectsthequalityoflife,buttheinstrument
is more complicated and correct completion may require
a trained member of the clinic/research team and not by
patients themselves. The NMS-S was not designed to be
administered to caregivers, as they are less apt than patients
to more fully understand both the severity and duration of
NMS that patients experience, which explains why there is
lower correlation between patient and caregiver scores using
the NMS-S than NMS-Q.
There were several limitations to our study. The small
sample size was the greatest limitation. Furthermore, the
prevalence of mood symptoms in this cohort may not have
been truly representative of the general advanced PD state
since unstable psychiatric illness and neuropsychological
issues were screened out as part of establishing DBS can-
didacy. The data do speak to how commonly NMS occurs
and that there may be issues with clinicians recognizing
these features especially when focusing on motor issues and,
interestingly, may be variably identiﬁed depending on which
scale or questionnaire they use. Clinicians providing care
and especially those providing DBS should be aware of the
instrument-dependent nature of their recognition of these
issues. The NMS-Q had better correlation between patients’
and caregivers’ reported symptoms, while the NMS-S oﬀers
the additional dimension of addressing severity of symptoms
that are identiﬁed.
In summary, while these 2 instruments have their
weaknesses and diﬀerences in instrument properties, they
have been used in previous epidemiological studies as a
basis for determining frequencies. We realize that while
our N is small and the population is indeed biased to the
“surgical patient.” this may prevent us from determining the
true prevalence of NMS in advanced PD and explains the
diﬀerence in results between our cohort and prior results
reported by Chaudhuri. Our emphasis was not as much on
the accurate accounting of each NMS, but more that, when
converting these scale responses to a simple “symptom is
present” versus “symptom is absent,” the responses indeed
varied even if the two instruments were administered by
the same individuals (patient and caregivers); literally, one
instrument right after the other.
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